Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
liposomal doxorubicin · 1 trial · 5 indications
| Name | Type | Description |
|---|---|---|
| Gemcitabine | DRUG | - |
| liposomal doxorubicin | DRUG | - |
Inclusion Criteria: * All patients must have a documented pathologic diagnosis of epithelial ovarian (FIGO Stage I-IV), Fallopian tube or primary peritoneal carcinoma * Patients must have received platinum-based, first-line chemotherapy but no more than one additional prior chemotherapy regimen. Pa...
Liposomal doxorubicin is used for genital neoplasms in females, specifically in the treatment of platinum-resistant ovarian, fallopian, or primary peritoneal cancer. It is an investigational small molecule being studied in oncology.
Liposomal doxorubicin is being developed by Eli Lilly and Company, which is publicly traded under the ticker LLY. The company is conducting clinical research on this drug for female genital neoplasms.
Liposomal doxorubicin is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 3 trial has been completed.
Liposomal doxorubicin has one completed Phase 3 trial, NCT00191607, which enrolled 162 female patients aged 18 years and older with platinum-resistant ovarian, fallopian, or primary peritoneal cancer. The trial was conducted in the United States.
Liposomal doxorubicin is a formulation of doxorubicin encapsulated in liposomes. While it contains the same active drug, the liposomal formulation alters its delivery and distribution. The data provided does not specify alternative names for this drug.